Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims focus on branding/trade names and formulation differentiation. The label supports Remeron and Remeron SolTab as brand/formulation names and confirms the generic name mirtazapine, and that RemeronSolTab denotes the orally disintegrating tablet. Several branding-related statements are not explicitly addressed in the US labeling or lie outside its scope, resulting in partial alignment.
Category Scores
Accurate Statements
Remeron and Remeron SolTab are listed as brand names in the FDA label.
The label lists brand names such as Remeron and Remeron SolTab (Remeron SolTab used for the orally disintegrating tablet).
The generic name shown on the label is mirtazapine.
The label identifies the generic name as mirtazapine.
Remeron SolTab is the name used for the orally disintegrating tablet formulation.
The label specifies REMERONSolTab as the orally disintegrating tablet formulation.
The label differentiates tablet formulations (Remeron standard vs REMERONSolTab).
The label lists Remeron tablets (15 mg, 30 mg) and REMERONSolTab as distinct formulations.
The label describes REMERON and REMERONSolTab content: mirtazapine.
DESCRIPTION indicates REMERON and REMERONSolTab contain mirtazapine.
Unsupported Statements
Remeron (and RemeronSolTab) are among the most recognized brand names.
The label does not discuss recognition or market prominence.
Mirtazapine is sold under multiple brand names depending on the country and manufacturer.
The label is US-specific and does not address country-by-country branding; claim partially supported by US branding only.
Specific trade names can vary by regulator and local licensing.
The label does not discuss cross-regulatory branding variation.
Companies can update branding, and new manufacturers can sell the same generic under different brand names.
Branding updates are not discussed in the US label.
That’s why the generic name stays consistent even when the trade name differs.
The label does not discuss generic naming consistency across brands.
Contradictions
Important Omissions
The evaluation includes branding statements but does not address indications, dosing specifics, and safety-related label content beyond branding. The branding-focused assessment omits non-branding label sections which could be material for a comprehensive evaluation.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated claims are branding-related and do not introduce dosing or safety information; no new risk is indicated by branding statements.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Branding statements are addressed, but several claims extend beyond the US label scope or discuss branding practices not covered in the label.
Suggested Improvement